$BSX · Boston Scientific Corporation
Boston Scientific Corporation, through its indirect wholly-owned finance subsidiary American Medical Systems Europe B.V., filed a preliminary prospectus supplement for an offering of euro-denominated notes. The offering includes floating rate notes and several series of fixed rate senior notes, all fully and unconditionally guaranteed by Boston Scientific. The filing is dated November 19, 2026, and the terms, including interest rates and maturity dates, were not yet finalized.
The company intends to use the net proceeds, together with other borrowings and cash on hand, to finance the cash consideration for its agreed acquisition of Penumbra, Inc. and to pay related fees and expenses. Any remaining proceeds may be used for general corporate purposes. The offering is not conditioned on completion of the Penumbra acquisition, and the proceeds will not be placed in escrow.
If the Penumbra acquisition is not completed by the applicable outside date or Boston Scientific decides not to pursue it, the fixed rate notes will be subject to a special mandatory redemption at 101% of their principal amount plus accrued interest. The floating rate notes are not redeemable before maturity except for certain tax events, and the notes include a change of control repurchase provision.